Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Biosimilar analytical similarity report arrived with a CRL citing manufacturing, not efficacy. 505(b)(2) development lead in a labeling team facing a boxed-warning debate still has an evidence gap on whether to drop a secondary endpoint that will dominate the AdCom.

DECISION 505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. Biosimilar analytical similarity report reads as Proceed under protocol once a CRL citing manufacturing, not efficacy is lined up to the same Pharma & Life Sciences population. 2. Biosimilar analytical similarity report is closer to Pause the pathway after a CRL citing manufacturing, not efficacy; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in biosimilar analytical similarity report for 505(b)(2) development lead in a labeling team facing a boxed-warning debate. 4. Biosimilar analytical similarity report is missing the fact 505(b)(2) development lead needs after a CRL citing manufacturing, not efficacy; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether biosimilar analytical similarity report supports the labeled claim 505(b)(2) development lead would keep. 3. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a CRL citing manufacturing, not efficacy and write the one fact that would move to drop a secondary for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a labeling team facing a boxed-warning debate.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in biosimilar analytical similarity report, then the action for 505(b)(2) development lead - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - CMC and Development Pathways finding in biosimilar analytical similarity report that a second reviewer can re-perform - Missing page in biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy, if any